Safety of Cerebrolysin^®

Cerebrolysin^® is safe and well tolerated!

The experience with Cerebrolysin^® during many years of clinical application, the information from post-marketing surveillance studies, and the safety data from double-blind, placebo-controlled clinical trials indicate an extremely high degree of safety (e.g. significat reduction of mortality in CASTA study¹).

According to EMA classification, Cerebrolysin^® is in the “SAFE” category (PSUR reporting required only every 13 years).

In general, reported adverse drug reactions from Cerebrolysin^® treated patients are transient and mild in intensity.

The most frequently reported adverse reactions with Cerebrolysin^® are

• dizziness
• headache
• sweating
• nausea

Please note that the handling is very important. Please find more information in our dosage recommendation.